Comparative Pharmacology
Head-to-head clinical analysis: RADIOGENIX SYSTEM versus TECHNETIUM TC 99M MEBROFENIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RADIOGENIX SYSTEM versus TECHNETIUM TC 99M MEBROFENIN.
RADIOGENIX SYSTEM vs TECHNETIUM TC-99M MEBROFENIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
None Documented
None Documented
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Technetium Tc-99m mebrofenin."
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Technetium Tc-99m mebrofenin."
Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance.
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion.
Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination.
Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical